An interventional study of Prolonged inflation and Rapid inflation in Coronary Artery Disease and Coronary Stent Occlusion, sponsored by Central Arkansas Veterans Healthcare System. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Central Arkansas Veterans Healthcare System · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,104 studies in Coronary Artery Disease with a site in United States — 99 open to participants now, 144 under way, 10 of them phase 3. Coronary Artery Disease · United States.
Among the 1,104 studies in Coronary Artery Disease with a site in United States, this one is the 548th largest by planned enrollment of the 745 interventional ones that give a count, is one of 5 that started in 2027, is one of 352 with no phase, reaches primary completion later than 110 of the 141 other live ones, and was the 599th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →99 of the 1,104 studies in Coronary Artery Disease with a site in United States are open now. Recruiting first, the newest first:
EBI Anti Sepsis BV · Sites in United States, Belgium, Netherlands and 1 more country
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 55+
Mayo Clinic · Sites in United States
Ages 40+
Eli Lilly and Company · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Australia, Germany and 2 more countries
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 104 · Phase 3 112 · Phase 4 141
First in 1985; this study’s year is marked. 5 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 107 across the 745 interventional studies, 186 across the 357 observational. Of the 840 that completed or were terminated, 355 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
378 of 1,104 have an industry lead sponsor. The 10 most frequent:
Central Arkansas Veterans Healthcare System is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Central Arkansas Veterans Healthcare System has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
51 of the studies in Coronary Artery Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357675Phase 3EBI Anti Sepsis BVA Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | 2027-10-01 |
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT06713239Cleerly, Inc.A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | 2026-12 |
| NCT03894423Stanford UniversityComprehensive Computed Tomography Guidance of Coronary Bypass Graft Surgery | 2026-12 |
| NCT07761728University of California, Los AngelesThe FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 1,104 studies in Coronary Artery Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It is universally accepted that high-pressure balloon inflation is required to most effectively deploy a coronary balloon-expandable stent. However, there is not consensus nor are there any guidelines regarding the method of balloon inflation, particularly the duration of inflation. Underexpansion and strut malapposition after stent deployment are among the most powerful predictors for adverse vessel outcomes. High-pressure inflation for stent deployment is effective to optimally expand the stent, but unlike in vitro testing in air, there are poorly distensible plaque elements that may not instantaneously yield to the balloon pressure. However, these elements may ultimately yield to prolonged inflation. Most clinical interventional cardiologists inflate for a relatively short period (15-30 sec). The investigators have noted that when balloon pressure is maintained at a certain pressure level it tends to decrease over time, and may require 60-180 or more seconds to maintain pressure stability. This finding implies that plaque elements are yielding slowly over time to the increased pressure, thus increasing expansion, and suggests that a prolonged inflation until balloon pressure stabilizes is more effective than a rapid inflation/deflation sequence to fully expand and appose the stent to the vessel wall. At present there is no consensus on stent deployment strategy. It is our hypothesis that prolonged inflation is superior to the more commonly used strategy of rapid inflation/deflation.
Optimal coherence tomography (OCT), a novel technology that measures near-infrared light reflections and translates them into a 2D image, has an axial resolution nearly 10-times that of intravascular ultrasound (IVUS). Thus it is possible to examine the extent of stent malposition and stent expansion using this modality.
The current randomized trial tests the hypothesis that prolonged balloon inflation until a stable balloon pressure is maintained is more effective than a rapid inflation/deflation sequence when performed to the same balloon inflation pressure.
The rapid inflation method (termed rapid) will consist of reaching a high-pressure (16 atmospheres)with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully deflated and longer only if the balloon requires a longer duration to become fully inflated. Based on previous data, the average time will likely be in the 20-30 sec range. Prolonged inflation (termed prolonged) will be performed at high pressure (16 atmospheres) and maintained for 30 sec with \<0.3 atmospheres drop during that period. For example, in the case of 16 atmospheres, the prolonged inflation will require a steady pressure of 15.8-16 atmospheres for at least 30 sec. If the inflation pressure falls 0.3 further pressure will be applied using the digital inflation device until it is again at the target pressure, resetting the 30 second clock. It should be emphasized that if at any time during prolonged inflation there is hemodynamic or electrocardiographic instability, the balloon will be deflated. Based on our previous experience we do not anticipate any safety issues; however, we will measure safety parameters as noted below. After either the rapid or prolonged inflation, an OCT run will be performed to delineate stent expansion and strut apposition. Should the operator determine that the OCT appearance of the stent is unsatisfactory, it is left to the operator to proceed as clinically required, using any further approaches, as he or she sees fit. The results of any further intervention, however, will not be included as part of the data analysis. The study period consists of randomization through the end of the coronary intervention within the catheterization laboratory, for both the efficacy and safety endpoint. The study period will be monitored continuously by a research coordinator and an investigator. All adverse events as described under Safety end points will be reported to the Institutional Review Board (IRB) as per the IRBs prescribed time frame.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients >18 years old with coronary disease with clinical indication for single stent placement in a lesion with a 2.5-3.5 mm diameter and who require OCT for determination of effective stent placement .
Exclusion Criteria:
1. ST segment elevation myocardial infarction 2. Chronic total occlusion 3. Bifurcation lesion or major side branch (>2.5 mm) within the stented area 4. Need for overlapping stents 5. Clinical instability including cardiogenic shock 6. Inability to give 7. Chronic kidney disease with serum creatinine >1.8 mg/dL 8. Unprotected left main stenosis
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
Other: Rapid inflation
Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
Other: Prolonged inflation
Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
Number of unopposed stent struts
How many stents are unopposed
Time frame: Day 1 Within first hour after after stent deployment
Minimal luminal stent area
Minimal area of the luminal stent area measured
Time frame: Day 1 Within first hour after after stent deployment
Minimal lumen stent diameter
Diameter measured
Time frame: Day 1 Within first hour after after stent deployment
Number of unopposed stent struts/mm of stent
How many unopposed stent struts are involved
Time frame: Day 1 Within first hour after stent deployment
% of patients with complete stent apposition
percentage of patients measured that have a complete stent apposition
Time frame: Day 1 Within first hour after stent deployment
Symptomatic ischemia requiring balloon deflation
ischemia requiring balloon deflation
Time frame: Intra-procedure
Serious arrhythmia
Serious arrhythmia during intervention
Time frame: Intra-procedure and first hour post-Percutaneous Coronary Intervention (PCI)
Plan to share: No — No Individual Participant Data (IPD) sharing plan at this time as the study has been placed on hold.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 23 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Arkansas Veterans Healthcare System